Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PROgastrine COlon DEpistage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03775473
Recruitment Status : Terminated (

COVID-19 pandemic has made it increasingly difficult for ECS progastrin to ensure clinical research is maintained.

As a result, the sponsor made the decision to end patient enrollment prematurely.

)
First Posted : December 14, 2018
Last Update Posted : January 27, 2022
Sponsor:
Collaborator:
Centre Hospitalier Princesse Grace
Information provided by (Responsible Party):
ECS-Progastrin SA

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Dosage of progastrin in asymptomatic person participating in colon cancer screening

Condition or disease Intervention/treatment Phase
Colon Cancer Screening Healthy Person Diagnostic Test: progastrin Not Applicable

Detailed Description:
For anyone who will participate in colon screening at the Princess Grace Hospital of Monaco and who has signed the informed consent document. A blood test will be performed in addition to the screening test to assess the rate of progastrin.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 260 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Interventional Research, at Risk and Minimal Constraints, Category 2
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Dosage of Progastrin in Asymptomatic Person Participating in Colon Cancer Screening
Actual Study Start Date : February 7, 2019
Actual Primary Completion Date : February 5, 2021
Actual Study Completion Date : December 17, 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
progastrin
anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
 Diagnostic Test: progastrin
PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. progastrin rate [ Time Frame: from 15 days to 2 months (until results are obtained) ]
    measuring the rate of progastrin in the blood


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • participant in colon cancer screening
  • signing informed consent

Exclusion Criteria:

  • any major medical, psychiatric or addictive illness that would affect the informed consent process
  • The consent of a representative is not allowed in this study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03775473


Locations
Layout table for location information
France
Centre Hospitalier Princesse Grace, Monaco
Montpellier, MC, France, 34070 MONTPELLIER
Sponsors and Collaborators
ECS-Progastrin SA
Centre Hospitalier Princesse Grace
Investigators
Layout table for investigator information
Principal Investigator: Georges GARNIER Centre Hospitalier Princesse Grace
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: ECS-Progastrin SA
ClinicalTrials.gov Identifier: NCT03775473    
Other Study ID Numbers: PROCODE
First Posted: December 14, 2018    Key Record Dates
Last Update Posted: January 27, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Monocentric study; No IPD sharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ECS-Progastrin SA:
progastrin
screening
bio-marker
healthy person
early stage
Additional relevant MeSH terms:
Layout table for MeSH terms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
 Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases